GPhA, BIO Join In Outlining Problems With House Compounding Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
The groups typically do not fall on the same side in policy fights, but say in a letter that compounding restrictions proposed in Rep. Griffith’s Compounding Clarity Act are “not that limiting.”
You may also be interested in...
News Briefs: Senate Introduces User Fee Bill; Lawsuit Ends Over Conflict Minerals
Senators try to shield FDA user fees from sequestration. Court rejects business groups’ challenge to conflict minerals reporting law. More news in brief
Track-and-Trace Bill Clears House With New Electronic Labeling Language
Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.
US FDA Holds First Hybrid Meeting With Industry
A Type A meeting was held in-person with a virtual contingent, the FDA clarified to the Pink Sheet. Several other meeting requests received were eligible, but did not seek an in-person session.